Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.34 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.33 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.33 |
| ▸ | AURKA | O14965 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
| ▸ | AKT1 | P31749 | 1/20 | 0.30 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
| ▸ | BCHE | P06276 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4909130 | 0.77 | — | — | |
| SCHEMBL4849063 | 0.76 | KDM4C (0.33) | KDM4CCDK5CDK5R1AURKAKDR | |
| SCHEMBL297602 | 0.73 | NISCH (0.48) | — | |
| SCHEMBL6766558 | 0.72 | KDM4C (0.36) | KDM4CCDK5CDK5R1AURKAKDR | |
| SCHEMBL450731 | 0.72 | KDM4C (0.33) | KDM4CCDK5CDK5R1AURKAKDR | |
| SCHEMBL2696780 | 0.69 | KDM4C (0.30) | KDM4C | |
| SCHEMBL690118 | 0.68 | CYP19A1 (0.53) | AURKAKDR | |
| SCHEMBL496792 | 0.68 | HDAC1 (0.31) | HDAC1HDAC6 | |
| SCHEMBL5986483 | 0.68 | PPARA (0.36) | — | |
| SCHEMBL291290 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113454081-A | Imidazopyridinyl compounds and their use for the treatment of proliferative diseases | 第一生物治疗股份有限公司 | 2021-09-28 | — | — | CN | claimed |
| CN-113454082-A | Imidazopyridinyl compounds and their use for the treatment of neurodegenerative diseases | 第一生物治疗股份有限公司 | 2021-09-28 | — | — | CN | claimed |
| EP-2566865-B1 | Thiazole derivatives as pest controller | BAYER IP GMBH (DE) | 2014-06-25 | — | — | EP | claimed |
| EP-1641792-B1 | PYRROLODIHYDROISOQUINOLINES AS PDE10 INHIBITORS | NYCOMED GMBH (DE) | 2010-08-25 | — | — | EP | claimed |
| US-7384942-B2 | 3-(2,4-dichlorophenyl)-5-bromoyrazine-2-ylamine; inhibiting the formation of neurofibrillary tangles; neurodegenerative, brain disorders; treatment of Alzheimer's disease with one or more additional agents donepezil or tacrine; anticarcinogenic, antiischemic, antidiabetic; insulin resistance | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-06-10 | — | — | US | claimed |
| EP-1237880-B1 | PYRAZINE BASED INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2008-01-23 | — | — | EP | claimed |
| US-20060135534-A1 | Pyrazine based inhibitors of glycogen synthase kinase 3 | CHIRON CORPORATION (US) | 2006-06-22 | — | — | US | claimed |
| US-7045519-B2 | Inhibitors of glycogen synthase kinase 3 | CHIRON CORPORATION (US) | 2006-05-16 | — | — | US | claimed |
| US-6989382-B2 | Carbocycle based inhibitors of glycogen synthase kinase 3 | CHIRON CORPORATION (US) | 2006-01-24 | — | — | US | claimed |
| EP-1607396-A1 | Bicyclic inhibitors of glycogen synthase kinase 3 | CHIRON CORPORATION (US) | 2005-12-21 | — | — | EP | claimed |
| WO-2002020495-A2 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | CHIRON CORPORATION (US) | 2002-03-14 | — | — | WO | claimed |
| US-20010044436-A1 | Bicyclic inhibitors of glycogen synthase kinase 3 | CHIRON CORPORATION | 2001-11-22 | — | — | US | claimed |
| US-20010034051-A1 | Pyrazine based inhibitors of glycogen synthase kinase 3 | CHIRON CORPORATION | 2001-10-25 | — | — | US | claimed |
| WO-2001044246-A1 | BICYCLIC INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | CHIRON CORPORATION (US) | 2001-06-21 | — | — | WO | claimed |
| WO-2001044206-A1 | PYRAZINE BASED INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | CHIRON CORPORATION (US) | 2001-06-21 | — | — | WO | claimed |
| EP-1087963-A1 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | Chiron Corporation (US) | 2001-04-04 | — | — | EP | claimed |
| WO-1999065897-A1 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | CHIRON CORPORATION (US) | 1999-12-23 | — | — | WO | claimed |
| EP-0784612-A1 | UREA DERIVATIVES AND THEIR USE AS ACAT-INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-07-23 | — | — | EP | claimed |
| WO-1996010559-A1 | UREA DERIVATIVES AND THEIR USE AS ACAT-INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-04-11 | — | — | WO | claimed |
| US-5001160-A | 1-aryl-1-hydroxy-1-substituted-3-(4-substituted-1-piperazinyl)-2-propanones and their use in treatment of neurogenic bladder disorders | MARION LABORATORIES, INC. (US) | 1991-03-19 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010034051-A1 | Pyrazine based inhibitors of glycogen synthase kinase 3 | GSK3B, GSK3A, GSKIP | KDM4C 3070/4885CDK5 141/4885CDK5R1 239/4885 |
| US-20010044436-A1 | Bicyclic inhibitors of glycogen synthase kinase 3 | GSK3A, GSK3B, GSKIP | KDM4C 2729/4885CDK5 195/4885CDK5R1 265/4885 |
| US-20060135534-A1 | Pyrazine based inhibitors of glycogen synthase kinase 3 | GSK3B, GSK3A, GSKIP | KDM4C 3070/4885CDK5 141/4885CDK5R1 239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.